Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

Eligibility Criteria

• * Physician-diagnosed asthma with duration of ≥12 months (based on the GINA 2024 Guidelines).
• * Currently receiving treatment with low, medium, to high dose ICS (equivalent ICS doses as per GINA 2024 Guidelines) in combination with at least 1 additional asthma controller medication for at least 60 days prior to the Screening.
• * Must have experienced at least 1 asthma exacerbation requiring the use of systemic corticosteroids (oral or parenteral) within the previous 12 months prior to Screening.
• * For participants who consent/assent to participate in the trial while in a stable condition, must have a documented historical peripheral blood eosinophil count of ≥250 cells/μL within 12 months prior to Screening.
• * Current acute asthma exacerbation requiring an urgent healthcare visit for treatment.
• * Peripheral blood eosinophil count of ≥300 cells/µL as part of the assessment of an index acute asthma exacerbation.
• * Requires systemic corticosteroid as SoC in the urgent healthcare setting to treat the current acute asthma exacerbation.
• * FEV1 ≥30% predicted prior to receiving IP.
• * Regular use of immunosuppressive medication 12 weeks or 5 half-lives prior to randomization, whichever is longer.
• * Unstable ischemic heart disease, cardiomyopathy, heart failure (New York Heart Association Class III or IV), uncontrolled hypertension.
• * Current or former smoker, has a smoking history including: If \<30 years old: Smoked for ≥5 pack-years; If ≥30 years old: Smoked for ≥10 pack-years
• * COPD and other clinically significant pulmonary disease other than asthma.
• * Known or suspected history of immunosuppression.
• * History of known immunodeficiency disorder (including HIV-1 or HIV-2). Known medical history of hepatitis B or C.
• * History of alcohol abuse and/or drug abuse within 12 months prior to Screening.
• * History of cancer except basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy \>1 year prior to entry or other malignancies treated with apparent success with curative therapy \>5 years prior to entry.
• * Female participant who is pregnant, lactating or breast-feeding, or has a positive urinary β hCG test prior to randomization.
• * Receipt of any marketed nonbiologic drug that modulates type 2 cytokines (eg, suplatast tosilate) 30 days or 5 half-lives prior to randomization, whichever is longer.
• * Receipt of any marketed biologic drug or any investigational biologic for asthma or other diseases within 16 weeks or 5 half-lives prior to randomization, whichever is longer.
• * Live, attenuated vaccinations within 4 weeks prior to randomization or planned live, attenuated vaccinations during the trial.
• * Participants that have been treated with bronchial thermoplasty in the last 12 months prior to Visit 1b.
• * Treatment with OCS and/or hospitalization for an exacerbation of asthma less than 4 weeks prior to randomization.
• * Receipt of any investigational nonbiologic drug within 30 days or 5 half-lives prior to randomization, whichever is longer.